Candel Therapeutics (CADL) Other Accumulated Expenses (2020 - 2025)

Candel Therapeutics has disclosed Other Accumulated Expenses across 5 years of filings, most recently posting $464000.0 for Q4 2025.

• Other Accumulated Expenses for Q4 2025 came in at $464000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $464000.0 (changed N/A YoY), and the FY2025 annual result was $464000.0, changed N/A from the prior year.
• Other Accumulated Expenses came in at $464000.0 for Q4 2025 at Candel Therapeutics, up from $55000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $464000.0 in Q4 2025 to a low of $31000.0 in Q3 2022.
• The 4-year median for Other Accumulated Expenses is $94000.0 (2022), against an average of $177600.0.
• Across the five-year window, Other Accumulated Expenses plunged 86.46% in 2022 and jumped 733.33% in 2023, its largest moves.
• Candel Therapeutics' Other Accumulated Expenses stood at $334000.0 in 2021, then tumbled by 85.63% to $48000.0 in 2022, then surged by 733.33% to $400000.0 in 2023, then increased by 16.0% to $464000.0 in 2025.
• The last three Other Accumulated Expenses figures came in at $464000.0 (Q4 2025), $55000.0 (Q3 2025), and $266000.0 (Q2 2025), per Business Quant data.